Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tempus AI

45.17
-3.9300-8.00%
Post-market: 44.00-1.1700-2.59%18:09 EDT
Volume:10.04M
Turnover:453.22M
Market Cap:7.78B
PE:-7.25
High:48.49
Open:48.06
Low:43.53
Close:49.10
Loading ...

Tempus AI Shares Fall 11.7% After 4Q Revenue Projections Fall Below Expectations

Dow Jones
·
13 Jan

Stock Track | Tempus AI Plummets 11.91% on CRO Revenue Softness Despite Overall Growth

Stock Track
·
13 Jan

Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH

Business Wire
·
13 Jan

Tempus AI Shares Down 4.7% Premarket After Co Announces Preliminary Q4 Results

THOMSON REUTERS
·
13 Jan

Tempus AI Inc - Q4 2024 Revenue Approximately $200 Million, 35% Growth YoY

THOMSON REUTERS
·
13 Jan

Tempus AI Inc - Sequential Improvement in Adjusted Ebitda in Q4 2024

THOMSON REUTERS
·
13 Jan

Stock Track | Tempus AI Sinks 5.36% in Pre-Market as Preliminary Results Show CRO Revenue Softness

Stock Track
·
13 Jan

Press Release: Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results

Dow Jones
·
13 Jan

Tempus AI Stock Falls Despite Collaboration Announcement With Genialis

Zacks
·
09 Jan

Tempus, Genialis Collaborate to Advance RNA-Based Biomarker Algorithms for Cancer Treatment

MT Newswires Live
·
09 Jan

Tempus AI teams with Genialis to develop RNA-based biomarker algorithms

TIPRANKS
·
08 Jan

Tempus Announces a Collaboration With Genialis to Develop Rna-Based Biomarker Algorithms

THOMSON REUTERS
·
08 Jan

Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

Business Wire
·
08 Jan

Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?

Zacks
·
08 Jan

President Capital Initiates Tempus AI at Buy With $52 Price Target

MT Newswires Live
·
07 Jan

Tempus AI up after FDA issues draft guidance on AI use in drug decision making

TIPRANKS
·
07 Jan